NovAliX and Inventiva Form a Strategic Alliance on Nuclear Receptors

After several years of successful collaboration in the field of nuclear receptors and a proven track record with three programs having reached clinical stage, Inventiva and NovAliX are now officially teaming up to establish a solid alliance to further deliver on the therapeutic promises of the nuclear receptor target class.

Through this alliance, Inventiva and NovAliX offer pharmaceutical and biotech companies a unique set of fully integrated nuclear receptor drug discovery capabilities by combining their respective in-depth expertise in structural biology, medicinal chemistry, biology, DMPK, pharmacology and safety. This alliance will leverage Inventiva’s and NovAliX’s diversified proprietary libraries in combination with complementary screening technologies (multiple biophysical techniques combined with biochemical and bio-functional assays). For the first time, pharmaceutical and biotech companies will be able to entrust their entire nuclear receptor drug discovery program from target validation to IND stage to one single experienced partner.

Pierre Broqua, CSO and co-founder of Inventiva, stated “This is a great opportunity for pharmaceutical and biotech companies wishing to engage in discovery collaborations to address this major, therapeutically relevant, target class. Based on our unique drug-discovery platform, proven track record in nuclear receptors, and our experience in managing collaborations, I strongly believe in our ability to again deliver innovative drug development candidates to our partners”.

Denis Zeyer, CEO of NovAliX, stated, “Ten years ago we built the company on the academic legacy of Pierre Chambon and Dino Moras, world class scientists, who pioneered the field of structural biology and nuclear receptors. We have turned that academic excellence into promising pharmaceutical candidates and this alliance is the opportunity to further extend that success”.